{"id":53816,"date":"2023-02-10T00:02:03","date_gmt":"2023-02-09T23:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/"},"modified":"2023-02-10T00:02:03","modified_gmt":"2023-02-09T23:02:03","slug":"sarissa-capital-does-not-believe-amarin-cares-about-shareholders","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/","title":{"rendered":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<b>Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting<\/b>\n<\/p>\n<p class=\"bwalignc\">\n<b>Amarin\u2019s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders<\/b>\n<\/p>\n<p class=\"bwalignc\">\n<b>Vote the BLUE proxy card \u201cFOR\u201d the appointment of the Sarissa Nominees and \u201cFOR\u201d the Removal of Chairman Per Wold-Olsen <span class=\"bwuline\">on or before February 21, 2023<\/span><\/b>\n<\/p>\n<p>GREENWICH, Conn.&#8211;(BUSINESS WIRE)&#8211;Sarissa Capital Management LP (\u201cSarissa\u201d) today issued the following letter to other shareholders of Amarin Corporation plc (NASDAQ: AMRN):\n<\/p>\n<p>\nDear Fellow Amarin Shareholders:\n<\/p>\n<p>\nWe, the owners, face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa\/Vazkepa, but the company continues to destroy value by mismanagement and poor capital allocation decisions. The company is in dire need of change, which even current leadership recognizes. And shareholders sent a loud and clear message in support of change at the annual meeting. However, the board spends millions of dollars of precious shareholder capital to keep shareholders off the board. Inexplicably, the board does not welcome the positive participation of its largest shareholder with a stellar track record of success.\n<\/p>\n<p>\nAmarin is at a critical juncture and risks further destruction of value unless we shareholders enact change now. Sarissa is seeking to remake the board by adding shareholder representatives who we believe will help maximize shareholder value and by removing Chairman Per Wold-Olsen. Our slate, including Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for nearly $10 billion, has the qualifications and experiences to help Amarin reach its true potential.\n<\/p>\n<p>\nSarissa urges shareholders to vote the BLUE proxy card \u201cFOR\u201d the appointment of the Sarissa Nominees and \u201cFOR\u201d the Removal of Chairman Per Wold-Olsen <b><span class=\"bwuline\">on or before February 21, 2023<\/span><\/b><span class=\"bwuline\">.<\/span>\n<\/p>\n<p>\nAs the general meeting approaches, we ask fellow shareholders separate Amarin\u2019s words from its actions. As we all know, actions speak louder than words. The actions of \u201cnew Amarin\u201d are marked by the same poor performance, missed goals and blatant disregard for shareholders as the \u201cold Amarin.\u201d Amarin\u2019s words are filled with inaccurate statements, empty promises and a lack of accountability.\n<\/p>\n<p>\n<b>Amarin has the audacity to state publicly, \u201c<!-- no quote -->the Company made solid progress in 2022, against its strategic objectives\u201d even though 2022 was terrible for shareholders by any objective measure:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn 2022, Amarin\u2019s stock price declined over 64%, wiping out more than $840 million of shareholder value.*\n<\/li>\n<li>\nIn June 2022, Amarin was 6 months late in announcing cost cuts in the US after a third generic entered and disrupted the market in January 2022. Entrance of the third generic was expected. The shareholder capital wasted due to the delay was an immense and avoidable destruction of shareholder value.\n<\/li>\n<li>\nThe European launch is off to a terrible start. Management could not convince Germany to reimburse Vazkepa even though, with the use of Vazkepa, Germany could save a significant portion of the &gt;\u20ac28 billion that it spends annually on cardiovascular disease.<sup>\u2020<\/sup> The rest of Europe is behind schedule, failing to live up to management\u2019s earlier promises.\n<\/li>\n<\/ul>\n<p>\n<b>Amarin\u2019s proclamation that its \u201c<!-- no quote -->Commitment to High Standards of Corporate Governance Drives Alignment and Accountability\u201d is inconsistent with their treatment of shareholders as Amarin has demonstrated time and time again that it dismisses shareholder interests:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe board continues to completely ignore the outcome of the most recent annual meeting where nearly 50% of all votes cast were either votes against the Amarin board or abstentions. Notably, this result occurred after Sarissa publicly stated that \u201c<!-- no quote -->we intend to vote \u2018ABSTAIN\u2019 as this reinforces our message that change is needed as we give the board time to add shareholder representatives.\u201d<sup>\u2021<\/sup> Yet, the board still refuses to add Sarissa representatives.\n<\/li>\n<li>\nWe believe the board\u2019s prolonged \u201cboard refreshment process\u201d was not legitimate. No shareholder representatives were added to the board and our input was never sought on any of their appointees. Sarissa is Amarin\u2019s largest shareholder, and we have a track record of creating shareholder value through board representation, including in the cardiovascular space. It is bewildering that Amarin remains obstinate and will not allow shareholder participation on the board.\n<\/li>\n<li>\nAmarin disclosed that it has spent more than $4 MILLION of shareholder capital and is planning to spend &gt;$7 MILLION total to prevent its largest shareholder from obtaining representation on the board. This amount is a whopping ~6X more than what Sarissa intends to spend in this proxy contest. Either Amarin does not know how to spend money efficiently or does not care about shareholders\u2019 money.\n<\/li>\n<\/ul>\n<p>\n<b>Amarin\u2019s assertion that \u201c<!-- no quote -->New Management Has Made Engagement a Top Priority\u201d is far from the truth as Amarin continues to make it difficult for shareholders, who are frustrated, to have a voice:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe board does not engage meaningfully with its shareholder base. Historically, barely 50% of the shareholders show up at any given shareholder meeting. Chairman Wold-Olsen and other directors have been dismissive of Amarin\u2019s shareholders as a \u201cretail\u201d shareholder base. \u201cRetail\u201d shareholders are owners of Amarin and are entitled to have their voices heard.\n<\/li>\n<li>\nAmarin delayed the disclosure of the record date for the general meeting, artificially established an earlier than necessary cut-off time for voting and delayed delivery of crucial shareholder lists requested by Sarissa. We believe Amarin\u2019s board is employing these tactics to uneven the playing field so that shareholders are unable to voice their dissatisfaction with the current regime. Amarin claims that these timelines are all required by UK law, which is canonically false, and they know it!\n<\/li>\n<li>\nAmarin has continuously misrepresented its interactions with Sarissa and Sarissa\u2019s track record of success as it attempts to smear us and our nominees. In our presentations, we exposed Amarin\u2019s misstatements, disinformation, and dishonesty, including by providing detailed accounts of our correspondence. Amarin attempts to sully our track record using wrong and misleading metrics. In fact, the average performance of our larger positions during the tenure of Sarissa and Sarissa designees is +39.7%.<sup>\u00a7<\/sup> In contrast, Amarin\u2019s performance under CEO Karim Mikhail and Chairman Per Wold-Olsen were -70.8% and -62.8% to year end 2022 respectively.<sup>\u2016<\/sup>\u00a0Amarin maintains that \u201c<!-- no quote -->we don\u2019t need Sarissa to maximize value.\u201d Again, actions speak louder than words.\n<\/li>\n<\/ul>\n<p>\nAmarin is in dire need of change. Sarissa believes the current regime is wasting a uniquely valuable opportunity. Vascepa is a highly attractive asset that can not only meaningfully improve patients\u2019 lives by reducing cardiovascular events but also save significant money for health systems worldwide. The board, led by Chairman Wold-Olsen, has failed shareholders and takes no accountability for its failures. Sarissa urges shareholders to act now to support change so that the current leadership does not continue its misguided stewardship of shareholder capital.\n<\/p>\n<p>\nWe look forward to continuing our engagement with our fellow shareholders. Thank you for your continued support.\n<\/p>\n<p>\nSarissa Capital Management LP<br \/>\n<br \/>#FreeAmarin\n<\/p>\n<p>\nVisit our website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.freeamarin.com&amp;esheet=53314160&amp;newsitemid=20230209005767&amp;lan=en-US&amp;anchor=www.freeamarin.com&amp;index=1&amp;md5=ce0c026fed89653c5b5e23ef9e5d1da0\" rel=\"nofollow noopener\" shape=\"rect\">www.freeamarin.com<\/a> for helpful information about Sarissa and the need for change at Amarin.\n<\/p>\n<p>\nVote the <b>BLUE<\/b> proxy card \u201c<b>FOR<\/b>\u201d the Sarissa Nominees and \u201c<b>FOR<\/b>\u201d the removal of Chairman Per Wold-Olsen.\n<\/p>\n<p>\nThe General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, <b><span class=\"bwuline\">SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023<\/span><\/b>.\n<\/p>\n<p>\nShareholders should be receiving the <b>BLUE<\/b> proxy card this week. If you do not receive your <b>BLUE<\/b> proxy card this week or have any questions on how to vote, please contact:\n<\/p>\n<p class=\"bwalignc\">\nD.F. King &amp; Co., Inc.<br \/>\n<br \/>48 Wall Street<br \/>\n<br \/>New York, New York 10005<br \/>\n<br \/><b>Shareholders call toll-free:<\/b> (800) 331-7024<br \/>\n<br \/><b>Banks and Brokers call:<\/b> (212) 269-5550<br \/>\n<br \/><b>By Email:<\/b> <a target=\"_blank\" href=\"m&#97;&#105;&#108;&#x74;&#x6f;&#x3a;AM&#82;&#78;&#x40;&#x64;&#x66;&#x6b;in&#103;&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x41;&#x4d;&#x52;&#x4e;&#x40;&#x64;&#x66;&#107;&#105;&#110;&#103;&#46;com<\/a>\n<\/p>\n<p>\n* Calculated from end of day December 31, 2021 \u2013 December 30, 2022. Source: Bloomberg<br \/>\n<br \/><sup>\u2020<\/sup> European Cardiovascular Disease Statistics 2017 edition<br \/>\n<br \/><sup>\u2021 <\/sup>Sarissa Capital Press Release June 15, 2022: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220615006073%2Fen%2FSarissa-Capital-Intends-to-Vote-%25E2%2580%259CAbstain%25E2%2580%259D-at-the-Amarin-Annual-Meeting&amp;esheet=53314160&amp;newsitemid=20230209005767&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220615006073%2Fen%2FSarissa-Capital-Intends-to-Vote-%25E2%2580%259CAbstain%25E2%2580%259D-at-the-Amarin-Annual-Meeting&amp;index=2&amp;md5=38dd264e91c45b8235c47868479cf763\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.businesswire.com\/news\/home\/20220615006073\/en\/Sarissa-Capital-Intends-to-Vote-%E2%80%9CAbstain%E2%80%9D-at-the-Amarin-Annual-Meeting<\/a><br \/><sup>\u00a7<\/sup> Calculated as average price change where a Sarissa or Sarissa-affiliated director held tenure as a board member, for larger Sarissa portfolio positions defined as (\u2265$50M), between the date immediately preceding their first date-in service and 12\/30\/2022. Not weighted by investment and not indicative of Sarissa\u2019s investment returns<br \/>\n<br \/><sup>\u2016<\/sup> Calculated as price change between the dates 7\/30\/2021 and 12\/30\/2022 for CEO Karim Mikhail and 1\/7\/2022 and 12\/30\/2022 for Per Wold-Olsen\n<\/p>\n<p>\n<b>Additional Information<\/b>\n<\/p>\n<p>\nSarissa Capital Management LP (\u201cSarissa Capital\u201d), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the \u201cCompany\u201d) at the general meeting of the Company for the election of Sarissa Capital\u2019s slate of highly-qualified nominees (the \u201cGeneral Meeting\u201d). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.\n<\/p>\n<p>\nThe definitive proxy statement and other relevant documents are available at no charge on the SEC\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53314160&amp;newsitemid=20230209005767&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=0fce6ad61d0626b01aef67ad6756cdfa\" rel=\"nofollow noopener\" shape=\"rect\">www.sec.gov<\/a> and at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.freeamarin.com&amp;esheet=53314160&amp;newsitemid=20230209005767&amp;lan=en-US&amp;anchor=www.freeamarin.com&amp;index=4&amp;md5=26f7049b5998adfa1f68f5f24544d764\" rel=\"nofollow noopener\" shape=\"rect\">www.freeamarin.com<\/a>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital\u2019s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nJean Puong<br \/>\n<br \/>Sarissa Capital Management LP<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#x3a;&#x69;&#x6e;&#x66;&#x6f;&#x40;sar&#105;&#115;&#115;&#97;&#x63;&#x61;&#x70;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;f&#x6f;&#x40;&#115;&#x61;r&#105;&#x73;&#115;&#x61;c&#97;&#x70;&#46;&#x63;o&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting Amarin\u2019s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders Vote the BLUE proxy card \u201cFOR\u201d the appointment of the Sarissa Nominees and \u201cFOR\u201d the Removal of Chairman Per Wold-Olsen on or &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53816","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting Amarin\u2019s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders Vote the BLUE proxy card \u201cFOR\u201d the appointment of the Sarissa Nominees and \u201cFOR\u201d the Removal of Chairman Per Wold-Olsen on or ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T23:02:03+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sarissa Capital Does Not Believe Amarin Cares About Shareholders\",\"datePublished\":\"2023-02-09T23:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/\"},\"wordCount\":1508,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/\",\"name\":\"Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-09T23:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarissa Capital Does Not Believe Amarin Cares About Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend","og_description":"Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting Amarin\u2019s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders Vote the BLUE proxy card \u201cFOR\u201d the appointment of the Sarissa Nominees and \u201cFOR\u201d the Removal of Chairman Per Wold-Olsen on or ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-09T23:02:03+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders","datePublished":"2023-02-09T23:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/"},"wordCount":1508,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/","url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/","name":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-09T23:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-does-not-believe-amarin-cares-about-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sarissa Capital Does Not Believe Amarin Cares About Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53816"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53816\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}